Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
1.995
+0.045 (2.31%)
Nov 21, 2024, 1:39 PM EST - Market open
Sangamo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 52.29 | 176.23 | 111.3 | 110.7 | 118.19 | 102.43 | Upgrade
|
| Revenue Growth (YoY) | -74.04% | 58.34% | 0.54% | -6.34% | 15.39% | 21.29% | Upgrade
|
| Cost of Revenue | 42.01 | 221.56 | 249.9 | 230.82 | 180.65 | 145.92 | Upgrade
|
| Gross Profit | 10.29 | -45.33 | -138.6 | -120.12 | -62.46 | -43.49 | Upgrade
|
| Selling, General & Admin | 45.16 | 57.17 | 62.68 | 63.22 | 67.1 | 61.69 | Upgrade
|
| Operating Expenses | 133.01 | 57.17 | 62.68 | 63.22 | 67.1 | 61.69 | Upgrade
|
| Operating Income | -122.72 | -102.49 | -201.28 | -183.34 | -129.55 | -105.18 | Upgrade
|
| Interest & Investment Income | 5.99 | 12.3 | 6.43 | 5.35 | 8.78 | 9.76 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.2 | -1.2 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -117.94 | -91.39 | -194.85 | -177.99 | -120.78 | -95.42 | Upgrade
|
| Merger & Restructuring Charges | -11.5 | -16.5 | - | - | - | - | Upgrade
|
| Impairment of Goodwill | - | -38.14 | - | - | - | - | Upgrade
|
| Asset Writedown | -5.82 | -116.88 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | 3 | - | - | - | Upgrade
|
| Pretax Income | -134.85 | -262.9 | -191.85 | -177.99 | -120.78 | -95.42 | Upgrade
|
| Income Tax Expense | -0.01 | -5.07 | 0.43 | 0.31 | 0.35 | - | Upgrade
|
| Earnings From Continuing Operations | -134.84 | -257.83 | -192.28 | -178.3 | -121.12 | -95.42 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 0.01 | 0.13 | 0.23 | Upgrade
|
| Net Income | -134.84 | -257.83 | -192.28 | -178.29 | -121 | -95.19 | Upgrade
|
| Net Income to Common | -134.84 | -257.83 | -192.28 | -178.29 | -121 | -95.19 | Upgrade
|
| Shares Outstanding (Basic) | 194 | 174 | 154 | 145 | 134 | 112 | Upgrade
|
| Shares Outstanding (Diluted) | 194 | 174 | 154 | 145 | 134 | 112 | Upgrade
|
| Shares Change (YoY) | 13.05% | 13.02% | 6.76% | 7.53% | 19.92% | 15.65% | Upgrade
|
| EPS (Basic) | -0.70 | -1.48 | -1.25 | -1.23 | -0.90 | -0.85 | Upgrade
|
| EPS (Diluted) | -0.70 | -1.48 | -1.25 | -1.23 | -0.90 | -0.85 | Upgrade
|
| Free Cash Flow | -117.11 | -246 | -243.8 | -256.53 | 155.16 | -165.08 | Upgrade
|
| Free Cash Flow Per Share | -0.61 | -1.41 | -1.58 | -1.77 | 1.15 | -1.47 | Upgrade
|
| Gross Margin | 19.67% | -25.72% | -124.53% | -108.51% | -52.84% | -42.46% | Upgrade
|
| Operating Margin | -234.69% | -58.16% | -180.85% | -165.61% | -109.61% | -102.69% | Upgrade
|
| Profit Margin | -257.86% | -146.30% | -172.76% | -161.05% | -102.37% | -92.93% | Upgrade
|
| Free Cash Flow Margin | -223.96% | -139.59% | -219.05% | -231.73% | 131.28% | -161.16% | Upgrade
|
| EBITDA | -117.03 | -87.43 | -189.17 | -173.9 | -123.87 | -101.25 | Upgrade
|
| EBITDA Margin | -223.80% | -49.61% | -169.97% | -157.09% | -104.80% | -98.85% | Upgrade
|
| D&A For EBITDA | 5.69 | 15.07 | 12.11 | 9.44 | 5.68 | 3.93 | Upgrade
|
| EBIT | -122.72 | -102.49 | -201.28 | -183.34 | -129.55 | -105.18 | Upgrade
|
| EBIT Margin | -234.69% | -58.16% | -180.85% | -165.61% | -109.61% | -102.69% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.